Company profile
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc.

Pipeline1 asset

  • onvansertibPLK1 / oral small-molecule PLK1 inhibitor / Oncology
    1L RAS-mutated metastatic colorectal cancerPhase 2randomized CRDF-0042L KRAS-mutated metastatic colorectal cancerPhase 1b/2completed2L metastatic colorectal cancerPhase 3ONSEMBLE/CRDF-003 randomized

Latest news14 items

All news

Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

-​ The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -​ -​ 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a dose-dependent improvement in efficacy, including confirmed ORR of 72.2%

Trial Results • Phase 2ASCO oral presentation Tue, Jun 2, 2026, 8:30 AM ET

Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings

Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update

Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004 trial in rapid oral presentation at American Society of Clinical Oncology Annual Meeting

Presentation / Abstract • Phase 2ASCO oral presentation Fri, May 29, 2026

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences

Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating: • Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev) • Significant improvement in PFS over combined SoC (HR: 0.37, p

Cardiff Oncology, Inc. • Endpoint Arena